A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

NCT00529581 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognition Disorders
Multiple Sclerosis

Interventions

DRUG: C105

Sponsor

Cognition Pharmaceuticals, LLC